Form 4: Coherus Oncology Director Georgia Erbez Granted 112,000 Stock Options

Coherus Oncology, Inc. Director Georgia Erbez was granted 112,000 stock options with an exercise price of $0.7904, which will fully vest on June 11, 2026.

Summary

• Georgia Erbez, a Director of Coherus Oncology, Inc. (CHRS), was granted 112,000 stock options.
• The transaction date for this grant was June 12, 2025.
• The exercise price for these stock options is $0.7904 per share.
• The options will vest and become exercisable as to 100% of the total number of shares on the one-year anniversary of June 11, 2025, which is June 11, 2026.
• Vesting is contingent upon Ms. Erbez's continued service relationship with Coherus Oncology, Inc. on the vesting date.
• The stock options have an expiration date of June 12, 2035.
• Following this transaction, Ms. Erbez beneficially owns 112,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a routine part of executive compensation, aligning the director's interests with long-term shareholder value. This is generally viewed as a neutral to slightly positive event as it reflects standard corporate governance and incentive practices.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Coherus Oncology, Inc.

Future Outlook

The document indicates that the granted stock options will vest on June 11, 2026, contingent on the director's continued service, providing a future incentive for long-term engagement.

Industry Context

The grant of stock options to a director is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of equity compensation to attract, retain, and incentivize key personnel by aligning their interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a typical component of executive and board compensation packages across the industry, including companies like Amgen, Gilead Sciences, and Biogen, which frequently use equity awards to incentivize long-term performance.
• The vesting schedule, contingent on continued service, is a common mechanism to ensure retention and sustained commitment, consistent with practices observed in comparable life sciences companies.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: While this specific grant is for a director, equity compensation is a common incentive tool across the company, potentially influencing overall compensation philosophy.

Next Steps

• The stock options will vest on June 11, 2026, subject to the director's continued service.
• Upon vesting, the director will have the right to exercise the options to acquire common stock at the specified exercise price until the expiration date of June 12, 2035.

Key Dates

Keywords

Coherus Oncology, CHRS, Stock Option, Director, Insider Transaction, Equity Compensation, Form 4, Georgia Erbez